Methamphetamine-induced dopamine-independent alterations in striatal gene expression in the 6- hydroxydopamine hemiparkinsonian rats

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Cadet, Jean Lud ^a   Brannock, Christie ^a   Krasnova, Irina N ^a   Ladenheim, Bruce ^a   McCoy, Michael T ^a   Chou, Jenny ^a   Lehrmann, Elin ^a   Wood, William H ^a   Becker, Kevin G ^a   Wang, Yun ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CYCLOOXYGENASE 2; DOPAMINE RECEPTOR; EARLY GROWTH RESPONSE FACTOR; FOLLISTATIN; METHAMPHETAMINE; NEUROMEDIN U; NUCLEAR RECEPTOR NR4A3; OXIDOPAMINE; PLATELET DERIVED GROWTH FACTOR D; PROTEIN C FOS; SEROTONIN; TACHYKININ; TACHYKININ 2; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; EARLY GROWTH RESPONSE FACTOR 1; EGR1 PROTEIN, RAT; NERVE PROTEIN; NR4A3 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; FOREBRAIN; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; MALE; MICROARRAY ANALYSIS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; RAT; UPREGULATION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DNA MICROARRAY; GENE EXPRESSION REGULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; METHODOLOGY; PARKINSON DISEASE; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DNA-BINDING PROTEINS; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION; MALE; METHAMPHETAMINE; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDOPAMINE; PARKINSON DISEASE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 78650792684     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015643     Document Type: Article

References (99)

1. Cardoso F (2009) Huntington disease and other choreas. Neurol Clin 27: 719-736.
2. Fahn S (2008) The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 23(Suppl 3): S497-S508.
3. Berger K, Przedborski S, Cadet JL (1991) Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res Bull 26: 301-307.
4. Cadet JL, Zhu SM (1992) The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rat. Brain Res 595: 316-326.
5. Cadet JL, Zhu SM, Angulo JA (1992) Quantitative in situ hybridization evidence for differential regulation of proenkephalin and dopamine D2 receptor mRNA levels in the rat striatum: effects of unilateral intrastriatal injections of 6-hydroxydopamine. Brain Res Mol Brain Res 12: 59-67.
6. Herrera-Marschitz M, Arbuthnott G, Ungerstedt U (2010) The rotational model and microdialysis: Significance for dopamine signalling, clinical studies, and beyond. Prog Neurobiol 90: 176-189.
7. Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367: 69-93.
8. Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24: 485-493.
9. Altar CA, Marien MR, Marshall JF (1987) Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J Neurochem 48: 390-399.
10. Angulo JA, Coirini H, Ledoux M, Schumacher M (1991) Regulation by dopaminergic neurotransmission of dopamine D2 mRNA and receptor levels in the striatum and nucleus accumbens of the rat. Brain Res Mol Brain Res 11: 161-166.
11. Chritin M, Feuerstein C, Savasta M (1993) Time-course of changes in striatal levels of DA uptake sites, DA D2 receptor and preproenkephalin mRNAs after nigrostriatal dopaminergic denervation in the rat. Brain Res Mol Brain Res 19: 318-322.
12. Graham WC, Crossman AR, Woodruff GN (1990) Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Res 514: 93-102.
13. Angulo JA, Davis LG, Burkhart BA, Christoph GR (1986) Reduction of striatal dopaminergic neurotransmission elevates striatal proenkephalin mRNA. Eur J Pharmacol 130: 341-343.
14. Campbell K, Wictorin K, Bjorklund A (1992) Differential regulation of neuropeptide mRNA expression in intrastriatal striatal transplants by host dopaminergic afferents. Proc Natl Acad Sci U S A 89: 10489-10493.
15. Morris BJ, Herz A, Hollt V (1989) Localization of striatal opioid gene expression, and its modulation by the mesostriatal dopamine pathway: an in situ hybridization study. J Mol Neurosci 1: 9-18.
16. Berke JD, Paletzki RF, Aronson GJ, Hyman SE, Gerfen CR (1998) A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci 18: 5301-5310.
17. El Atifi-Borel M, Buggia-Prevot V, Platet N, Benabid AL, Berger F, et al. (2009) De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat. Neurobiol Dis 34: 340-350.
18. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, et al. (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250: 1429-1432.
19. Konradi C, Westin JE, Carta M, Eaton ME, Kuter K, et al. (2004) Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis 17: 219-236.
20. Paul ML, Graybiel AM, David JC, Robertson HA (1992) D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. J Neurosci 12: 3729-3742.
21. Bustamante D, You ZB, Castel MN, Johansson S, Goiny M, et al. (2002) Effect of single and repeated methamphetamine treatment on neurotransmitter release in substantia nigra and neostriatum of the rat. J Neurochem 83: 645-654.
22. Kuczenski R, Segal DS, Cho AK, Melega W (1995) Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15: 1308-1317.
23. Stephans SE, Yamamoto BK (1994) Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse 17: 203-209.
24. Zetterstrom T, Herrera-Marschitz M, Ungerstedt U (1986) Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Res 376: 1-7.
25. Zetterstrom T, Sharp T, Marsden CA, Ungerstedt U (1983) In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after d-amphetamine. J Neurochem 41: 1769-1773.
26. Shimada A, Yamaguchi K, Yanagita T (1996) Neurochemical analysis of the psychotoxicity of methamphetamine and cocaine by microdialysis in the rat brain. Ann N Y Acad Sci 801: 361-370.
27. Abekawa T, Ohmori T, Koyama T (1994) Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens. Brain Res 643: 276-281.
28. Nash JF, Yamamoto BK (1992) Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res 581: 237-243.
29. Beauvais G, Jayanthi S, McCoy MT, Ladenheim B, Cadet JL (2010) Differential effects of methamphetamine and SCH23390 on the expression of members of IEG families of transcription factors in the rat striatum. Brain Res 1318: 1-10.
30. Cadet JL, Jayanthi S, McCoy MT, Vawter M, Ladenheim B (2001) Temporal profiling of methamphetamine-induced changes in gene expression in the mouse brain: evidence from cDNA array. Synapse 41: 40-48.
31. Jayanthi S, McCoy MT, Beauvais G, Ladenheim B, Gilmore K, et al. (2009) Methamphetamine induces dopamine D1 receptor-dependent endoplasmic reticulum stress-related molecular events in the rat striatum. PLoS One 4: e6092.
32. Wang JQ, McGinty JF (1995) Dose-dependent alteration in zif/268 and preprodynorphin mRNA expression induced by amphetamine or methamphetamine in rat forebrain. J Pharmacol Exp Ther 273: 909-917.
33. Wang JQ, McGinty JF (1996) Acute methamphetamine-induced zif/268, preprodynorphin, and preproenkephalin mRNA expression in rat striatum depends on activation of NMDA and kainate/AMPA receptors. Brain Res Bull 39: 349-357.
34. Li SJ, Jiang HK, Stachowiak MS, Hudson PM, Owyang V, et al. (1990) Influence of nigrostriatal dopaminergic tone on the biosynthesis of dynorphin and enkephalin in rat striatum. Brain Res Mol Brain Res 8: 219-225.
35. Chritin M, Blanchard V, Raisman-Vozari R, Feuerstein C, Agid Y, et al. (1996) DA uptake sites, D1 and D2 receptors, D2 and preproenkephalin mRNAs and Fos immunoreactivity in rat striatal subregions after partial dopaminergic degeneration. Eur J Neurosci 8: 2511-2520.
36. Krasnova IN, Betts ES, Dada A, Jefferson A, Ladenheim B, et al. (2007) Neonatal dopamine depletion induces changes in morphogenesis and gene expression in the developing cortex. Neurotox Res 11: 107-130.
37. Krasnova IN, Justinova Z, Ladenheim B, Jayanthi S, McCoy MT, et al. (2010) Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat. PLoS One 5: e8790.
38. Cadet JL, McCoy MT, Cai NS, Krasnova IN, Ladenheim B, et al. (2009) Methamphetamine preconditioning alters midbrain transcriptional responses to methamphetamine-induced injury in the rat striatum. PLoS One 4: e7812.
39. Krasnova IN, Li SM, Wood WH, McCoy MT, Prabhu VV, et al. (2008) Transcriptional responses to reinforcing effects of cocaine in the rat hippocampus and cortex. Genes Brain Behav 7: 193-202.
40. Karstaedt PJ, Kerasidis H, Pincus JH, Meloni R, Graham J, et al. (1994) Unilateral destruction of dopamine pathways increases ipsilateral striatal serotonin turnover in rats. Exp Neurol 126: 25-30.
41. Adams DH, Hanson GR, Keefe KA (2001) Differential effects of cocaine and methamphetamine on neurotensin/neuromedin N and preprotachykinin messenger RNA expression in unique regions of the striatum. Neuroscience 102: 843-851.
42. O'Donovan KJ, Tourtellotte WG, Millbrandt J, Baraban JM (1999) The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience. Trends Neurosci 22: 167-173.
43. Cameron VA, Nishimura E, Mathews LS, Lewis KA, Sawchenko PE, et al. (1994) Hybridization histochemical localization of activin receptor subtypes in rat brain, pituitary, ovary, and testis. Endocrinology 134: 799-808.
44. Meurers BH, Dziewczapolski G, Shi T, Bittner A, Kamme F, et al. (2009) Dopamine depletion induces distinct compensatory gene expression changes in DARPP-32 signal transduction cascades of striatonigral and striatopallidal neurons. J Neurosci 29: 6828-6839.
45. Bean AJ, During MJ, Deutch AY, Roth RH (1989) Effects of dopamine depletion on striatal neurotensin: biochemical and immunohistochemical studies. J Neurosci 9: 4430-4438.
46. Hanson GR, Keefe KA (1999) Dopamine D-1 regulation of caudate neurotensin mRNA in the presence or absence of the nigrostriatal dopamine pathway. Brain Res Mol Brain Res 66: 111-121.
47. Burgunder JM, Young WS (1989) Distribution, projection and dopaminergic regulation of the neurokinin B mRNA-containing neurons of the rat caudateputamen. Neuroscience 32: 323-335.
48. Gerfen CR, McGinty JF, Young WS (1991) Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J Neurosci 11: 1016-1031.
49. Castel MN, Morino P, Dagerlind A, Hokfelt T (1994) Up-regulation of neurotensin mRNA in the rat striatum after acute methamphetamine treatment. Eur J Neurosci 6: 646-656.
50. Adams DH, Hanson GR, Keefe KA (2005) 3,4-Methylenedioxymethamphetamine increases neuropeptide messenger RNA expression in rat striatum. Brain Res Mol Brain Res 133: 131-142.
51. Garcia-Arencibia M, Ferraro L, Tanganelli S, Fernandez-Ruiz J (2008) Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats. Neurosci Lett 438: 10-13.
52. Meshul CK, Emre N, Nakamura CM, Allen C, Donohue MK, et al. (1999) Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 88: 1-16.
53. Touchon JC, Holmer HK, Moore C, McKee BL, Frederickson J, et al. (2005) Apomorphine-induced alterations in striatal and substantia nigra pars reticulata glutamate following unilateral loss of striatal dopamine. Exp Neurol 193: 131-140.
54. Yang J, Hu LF, Liu X, Zhou F, Ding JH, et al. (2006) Effects of iptakalim on extracellular glutamate and dopamine levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Life Sci 78: 1940-1944.
55. Paulsen RF, Granas K, Johnsen H, Rolseth V, Sterri S (1995) Three related brain nuclear receptors, NGFI-B, Nurr1, and NOR-1, as transcriptional activators. J Mol Neurosci 6: 249-255.
56. Budhiraja S, Chugh A (2009) Neuromedin U: physiology, pharmacology and therapeutic potential. Fundam Clin Pharmacol 23: 149-157.
57. Minamino N, Kangawa K, Matsuo H (1985) Neuromedin U-8 and U-25: novel uterus stimulating and hypertensive peptides identified in porcine spinal cord. Biochem Biophys Res Commun 130: 1078-1085.
58. Conlon JM, Domin J, Thim L, Di Marzo V, Morris HR, et al. (1988) Primary structure of neuromedin U from the rat. J Neurochem 51: 988-991.
59. Domin J, Ghatei MA, Chohan P, Bloom SR (1987) Neuromedin U-a study of its distribution in the rat. Peptides 8: 779-784.
60. Minamino N, Kangawa K, Honzawa M, Matsuo H (1988) Isolation and structural determination of rat neuromedin U. Biochem Biophys Res Commun 156: 355-360.
61. Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Habata Y, et al. (2000) Identification of neuromedin U as the cognate ligand of the orphan G proteincoupled receptor FM-3. J Biol Chem 275: 21068-21074.
62. Malendowicz LK, Nussdorfer GG, Markowska A, Tortorella C, Nowak M, et al. (1994) Effects of neuromedin U (NMU)-8 on the rat hypothalamo-pituitaryadrenal axis. Evidence of a direct effect of NMU-8 on the adrenal gland. Neuropeptides 26: 47-53.
63. Peier A, Kosinski J, Cox-York K, Qian Y, Desai K, et al. (2009) The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2). Endocrinology 150: 3101-3109.
64. Howard AD, Wang R, Pong SS, Mellin TN, Strack A, et al. (2000) Identification of receptors for neuromedin U and its role in feeding. Nature 406: 70-74.
65. Shan L, Qiao X, Crona JH, Behan J, Wang S, et al. (2000) Identification of a novel neuromedin U receptor subtype expressed in the central nervous system. J Biol Chem 275: 39482-39486.
66. Gartlon J, Szekeres P, Pullen M, Sarau HM, Aiyar N, et al. (2004) Localisation of NMU1R and NMU2R in human and rat central nervous system and effects of neuromedin-U following central administration in rats. Psychopharmacology (Berl) 177: 1-14.
67. Bilezikjian LM, Blount AL, Corrigan AZ, Leal A, Chen Y, et al. (2001) Actions of activins, inhibins and follistatins: implications in anterior pituitary function. Clin Exp Pharmacol Physiol 28: 244-248.
68. Bilezikjian LM, Blount AL, Leal AM, Donaldson CJ, Fischer WH, et al. (2004) Autocrine/paracrine regulation of pituitary function by activin, inhibin and follistatin. Mol Cell Endocrinol 225: 29-36.
69. Harrison CA, Gray PC, Vale WW, Robertson DM (2005) Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab 16: 73-78.
70. Bernard DJ, Chapman SC, Woodruff TK (2001) Mechanisms of inhibin signal transduction. Recent Prog Horm Res 56: 417-450.
71. Bilezikjian LM, Blount AL, Donaldson CJ, Vale WW (2006) Pituitary actions of ligands of the TGF-beta family: activins and inhibins. Reproduction 132: 207-215.
72. Xia Y, Schneyer AL (2009) The biology of activin: recent advances in structure, regulation and function. J Endocrinol 202: 1-12.
73. Tretter YP, Munz B, Hubner G, ten Bruggencate G, Werner S, et al. (1996) Strong induction of activin expression after hippocampal lesion. Neuroreport 7: 1819-1823.
74. Bottner M, Dubal DB, Rau SW, Suzuki S, Wise PM (2006) Stroke injury in rats causes an increase in activin A gene expression which is unaffected by oestradiol treatment. J Neuroendocrinol 18: 97-103.
75. Mukerji SS, Katsman EA, Wilber C, Haner NA, Selman WR, et al. (2007) Activin is a neuronal survival factor that is rapidly increased after transient cerebral ischemia and hypoxia in mice. J Cereb Blood Flow Metab 27: 1161-1172.
76. Thomas DM, Francescutti-Verbeem DM, Liu X, Kuhn DM (2004) Identification of differentially regulated transcripts in mouse striatum following methamphetamine treatment-an oligonucleotide microarray approach. J Neurochem 88: 380-393.
77. Ishida Y, Todaka K, Kuwahara I, Ishizuka Y, Hashiguchi H, et al. (1998) Methamphetamine induces fos expression in the striatum and the substantia nigra pars reticulata in a rat model of Parkinson's disease. Brain Res 809: 107-114.
78. Gardier AM, Moratalla R, Cuellar B, Sacerdote M, Guibert B, et al. (2000) Interaction between the serotoninergic and dopaminergic systems in dfenfluramine-induced activation of c-fos and jun B genes in rat striatal neurons. J Neurochem 74: 1363-1373.
79. Rouillard C, Bovetto S, Gervais J, Richard D (1996) Fenfluramine-induced activation of the immediate-early gene c-fos in the striatum: possible interaction between serotonin and dopamine. Brain Res Mol Brain Res 37: 105-115.
80. Konradi C, Leveque JC, Hyman SE (1996) Amphetamine and dopamineinduced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. J Neurosci 16: 4231-4239.
81. Collins S, Lutz MA, Zarek PE, Anders RA, Kersh GJ, et al. (2008) Opposing regulation of T cell function by Egr-1/NAB2 and Egr-2/Egr-3. Eur J Immunol 38: 528-536.
82. Zhang WQ, Tilson HA, Nanry KP, Hudson PM, Hong JS, et al. (1988) Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res 461: 335-342.
83. Bergsten E, Uutela M, Li X, Pietras K, Ostman A, et al. (2001) PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 3: 512-516.
84. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316.
85. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22: 1276-1312.
86. Enge M, Wilhelmsson U, Abramsson A, Stakeberg J, Kuhn R, et al. (2003) Neuron-specific ablation of PDGF-B is compatible with normal central nervous system development and astroglial response to injury. Neurochem Res 28: 271-279.
87. Woodruff RH, Fruttiger M, Richardson WD, Franklin RJ (2004) Plateletderived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. Mol Cell Neurosci 25: 252-262.
88. Funa K, Yamada N, Brodin G, Pietz K, Ahgren A, et al. (1996) Enhanced synthesis of platelet-derived growth factor following injury induced by 6-hydroxydopamine in rat brain. Neuroscience 74: 825-833.
89. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, et al. (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15: 1913-1925.
90. Sjoborg M, Pietz K, Ahgren A, Yamada N, Lindvall O, et al. (1998) Expression of platelet-derived growth factor after intrastriatal ibotenic acid injury. Exp Brain Res 119: 245-250.
91. Krasnova IN, Cadet JL (2009) Methamphetamine toxicity and messengers of death. Brain Res Rev 60: 379-407.
92. Kita T, Shimada K, Mastunari Y, Wagner GC, Kubo K, et al. (2000) Methamphetamine-induced striatal dopamine neurotoxicity and cyclooxygenase-2 protein expression in BALB/c mice. Neuropharmacology 39: 399-406.
93. Thomas DM, Kuhn DM (2005) Cyclooxygenase-2 is an obligatory factor in methamphetamine-induced neurotoxicity. J Pharmacol Exp Ther 313: 870-876.
94. Thomas DM, Francescutti-Verbeem DM, Kuhn DM (2006) Gene expression profile of activated microglia under conditions associated with dopamine neuronal damage. Faseb J 20: 515-517.
95. Simola N, Di Chiara G, Daniels WM, Schallert T, Morelli M (2009) Priming of rotational behavior by a dopamine receptor agonist in Hemiparkinsonian rats: movement-dependent induction. Neuroscience 158: 1625-1631.
96. Paul ML, Currie RW, Robertson HA (1995) Priming of a D1 dopamine receptor behavioural response is dissociated from striatal immediate-early gene activity. Neuroscience 66: 347-359.
97. Azdad K, Chavez M, Don Bischop P, Wetzelaer P, Marescau B, et al. (2009) Homeostatic plasticity of striatal neurons intrinsic excitability following dopamine depletion. PLoS One 4: e6908.
98. Centonze D, Gubellini P, Rossi S, Picconi B, Pisani A, et al. (2005) Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism. Neuroscience 133: 831-840.
99. Day M, Wang Z, Ding J, An X, Ingham CA, et al. (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9: 251-259.